Liu Shuang, Yin Hexuan, Ji Hongying, Zhu Jiaqi, Ma Rong
Department of Gynaecology and Obstetrics, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang 150081, P.R. China.
Exp Ther Med. 2018 Oct;16(4):3034-3040. doi: 10.3892/etm.2018.6541. Epub 2018 Jul 30.
Tripartite motif-containing 44 (TRIM44) has been demonstrated to be important in tumor metastasis and progression. However, the expression pattern and prognostic value of the expression of TRIM44 in epithelial ovarian cancer (EOC) remain to be fully elucidated. In the present study, the aim was to investigate the expression and clinical role of TRIM44 in EOC. A total of 109 patients, who underwent primary surgery with the goal of maximal tumor resection followed by standard combination chemotherapy with carboplatin and paclitaxel, were analyzed in the present study. The expression level of TRIM44 was determined by western blot analysis and immunohistochemistry in 109 ECO tissues. It was found that the expression of TRIM44 was low in normal tissues and high in EOC tissues. Univariate survival analysis showed that the overexpression of TRIM44 was significantly associated with International Federation of Gynecology and Obstetrics stage and lymph node metastasis (P<0.05). Kaplan-Meier analysis suggested that there was a significant difference in overall survival and disease-free survival rates between patients with a high expression of TRIM44 and patients with a low expression of TRIM44. Patients with a high expression level of TRIM44 exhibited poorer overall survival and disease-free survival rates, compared with patients expressing a low level of TRIM44 (P<0.001). In addition, the results of the multivariate analysis revealed that the predictive value of the expression of TRIM44 was independent of other clinicopathological factors for predicting prognosis. These findings demonstrated that a high expression of TRIM44 was associated with the progression and prognosis of EOC.
含三联基序蛋白44（TRIM44）已被证明在肿瘤转移和进展中起重要作用。然而，TRIM44在上皮性卵巢癌（EOC）中的表达模式及其表达的预后价值仍有待充分阐明。在本研究中，目的是探讨TRIM44在EOC中的表达及临床作用。本研究共分析了109例患者，这些患者接受了以最大程度切除肿瘤为目标的初次手术，随后接受了卡铂和紫杉醇的标准联合化疗。通过蛋白质印迹分析和免疫组织化学法测定了109例EOC组织中TRIM44的表达水平。发现TRIM44在正常组织中表达低，而在EOC组织中表达高。单因素生存分析显示，TRIM44的过表达与国际妇产科联盟分期和淋巴结转移显著相关（P<0.05）。Kaplan-Meier分析表明，TRIM44高表达患者与低表达患者的总生存率和无病生存率存在显著差异。与TRIM44低表达患者相比，TRIM44高表达水平的患者总生存率和无病生存率较差（P<0.001）。此外，多因素分析结果显示，TRIM44表达的预测价值独立于其他用于预测预后的临床病理因素。这些发现表明，TRIM44的高表达与EOC的进展和预后相关。
